Xylem (XYL) Posted Stronger EPS, Is The Stock Cheap?

Simply Wall St · 11/07 16:27

Xylem (XYL) has just reported stronger third quarter earnings per share from continuing operations of US$1.25, compared with US$0.93 a year earlier, while trimming its full year 2026 revenue outlook.

The latest earnings update lands after a choppy stretch for Xylem’s stock, with the share price falling 28.65% year to date and the 1 year total shareholder return down 34.44%, even though the 3 year total shareholder return is still slightly positive at 3.13%.

Scan how Xylem’s reset guidance compares with other potential opportunities by lining it up against our curated 39 high quality undervalued stocks that currently score well on quality and valuation support.

Profit is moving one way, guidance is edging the other, and Xylem now trades at a sizeable discount to both intrinsic value estimates and analyst targets. Is that pricing in real risk, or has caution swung too far?

Most Popular Narrative: 37% Undervalued

Against a last close of $97.83, the most followed narrative on Xylem argues for a fair value of $155 per share, which frames today’s discount as substantial and intentional rather than a rounding error.

Investment thesis:

Xylem is a high-quality water-infrastructure company benefiting from essential municipal, industrial, commercial and residential water spending. Long-term demand is supported by ageing water infrastructure, water scarcity, water-treatment requirements, digital monitoring and rising data-centre water demand. The thesis depends on converting these structural trends into steady growth, margin improvement, strong free cash flow and disciplined acquisitions.

See why 4 investors see Xylem as 37% undervalued.

According to Womble, the narrative behind that $155 fair value leans heavily on Xylem turning structural water needs into consistent earnings growth, solid free cash flow and disciplined use of capital. That view also assumes the Cornell Pump and Roper Pump acquisition, priced at $1.5b, delivers acceptable returns rather than simply adding debt and integration work.

The same thesis sets clear tripwires that would challenge the current undervalued tag. Persistent revenue contraction, weaker free cash flow than earnings, falling returns on capital or a poorly executed acquisition would all cut against the idea that the present 36.9% discount is a mispricing rather than a warning signal.

On today’s numbers, this narrative still lines up with several current datapoints. Xylem reports annual revenue of $9.06b and net income of $1.08b, with net profit margins at 11.9% compared with 10.7% a year earlier. Earnings growth over the past 5 years averaged 23.8% per year according to the statements, and the firm is described as having high quality earnings and a reliable 1.76% dividend, which fits with the cash conversion and dividend coverage pillars in the thesis.

The valuation view from Womble also sits broadly in the same range as other reference points. The SWS fair value of about $159.78 and analyst consensus of roughly $153.88 both cluster near the $155 narrative mark, even though analyst targets currently show limited agreement and are more than 20% above the market price. That alignment between different fair value estimates is part of what underpins the idea that Xylem is trading at a meaningful markdown rather than a modest discount.

Result: Fair Value of $155 (UNDERVALUED)

Still, the Xylem narrative can flip quickly if revenue growth slows materially below recent expectations or if the Cornell Pump deal underdelivers on returns.

Find out about the key risks to this Xylem narrative.

Next Steps

Sentiment in the Xylem story so far leans optimistic, yet the gap between price and fair value remains wide enough for debate. Act quickly, check the numbers for yourself, and then weigh up the 5 key rewards.

Looking for more investment ideas beyond Xylem?

If you stop with Xylem, you only see one angle. Broaden your watchlist and let data, not noise, guide where you look next.